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Reactive speciesFabry disease is an X-linked inborn error of glycosphingolipid catabolism due to deﬁcient activity of α-
galactosidase A that leads to accumulation of the enzyme substrates, mainly globotriaosylceramide (Gb3),
in body ﬂuids and lysosomes of many cell types. Some pathophysiology hypotheses are intimately linked
to reactive species production and inﬂammation, but until this moment there is no in vivo study about it.
Hence, the aim of this study was to investigate oxidative stress parameters, pro-inﬂammatory cytokines
and Gb3 levels in Fabry patients under treatment with enzyme replacement therapy (ERT) and ﬁnally to es-
tablish a possible relation between them. We analyzed urine and blood samples of patients under ERT
(n=14) and healthy age-matched controls (n=14). Patients presented decreased levels of antioxidant de-
fenses, assessed by reduced glutathione (GSH), glutathione peroxidase (GPx) activity and increased superox-
ide dismutase/catalase (SOD/CAT) ratio in erythrocytes. Concerning to the damage to biomolecules (lipids
and proteins), we found that plasma levels of malondialdehyde (MDA) and protein carbonyl groups and
di-tyrosine (di-Tyr) in urine were increased in patients. The pro-inﬂammatory cytokines IL-6 and TNF-α
were also increased in patients. Urinary Gb3 levels were positively correlated with the plasma levels of IL-
6, carbonyl groups and MDA. IL-6 levels were directly correlated with di-Tyr and inversely correlated with
GPx activity. This data suggest that pro-inﬂammatory and pro-oxidant states occur, are correlated and
seem to be induced by Gb3 in Fabry patients.
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Fabry disease (FD) is an X-linked inborn error of glycosphingolipid
catabolism due to deﬁcient activity of α-galactosidase A (EC 3.2.1.22).
This defect leads to a progressive accumulation of substrates, mainly
globotriaosylceramide (Gb3), in body ﬂuids and lysosomes of vascular
endothelium and most other tissues. Clinical manifestations include
pain and paresthesias in the extremities, angiokeratomas in skin and
mucous membranes, hypohidrosis and corneal opacity [1]. Since 2001,
enzyme replacement therapy (ERT) is available for FD. The treatment
consists in intravenous infusion of recombinant human α-
galactosidase A, every two weeks. Agalsidase beta and agalsidase alfa
are the two recombinant forms of α-galactosidase A in use for FD [2].
Although it is known that Fabry patients usually die in adult life
from renal, cardiac and/or cerebral complications of the vascular dis-
ease [1], the pathophysiology of the disease is largely unknown. There
is some evidence in the literature demonstrating that oxidative stress
227G.B. Biancini et al. / Biochimica et Biophysica Acta 1822 (2012) 226–232may be involved in FD pathophysiology. Moore et al. [3] found that
ascorbate, a potent antioxidant, decreases hyperperfusion in Fabry
patients under ERT treatment. In this context, Bodary et al. [4] dem-
onstrated, in apolipoprotein-E (apo-E) deﬁcient mice, that α-
galactosidase A deﬁciency accelerates atherosclerosis and causes in-
creased nitrotyrosine in the plaque. Moore et al. [5] also found excess
dermal vascular nitrotyrosine in biopsies from Fabry patients. It is al-
ready known that reactive species are involved in a great number of
chronic-inﬂammatory and vascular diseases [6,7]. Also, some studies
have shown that lysosomes are quite vulnerable to oxidative stress
and the lysosomal compartment is, at the same time, a place with
many favorable conditions to pro-oxidant state and even Fenton reac-
tion [8–10].
An in vitro study from Shen et al. [11] demonstrates that Gb3 in-
creases reactive oxygen species (ROS) generation and adhesion mol-
ecules expression in cultured Fabry endothelial cells. Also, the authors
found that plasma from patients treated with ERT increased ROS gen-
eration in cultured endothelial cells when compared to plasma from
controls.
Considering that oxidative stress is probably involved in Fabry dis-
ease but there are a few studies relating it directly, the aim of this
study was to evaluate and correlate oxidative damage to biomole-
cules, antioxidant defenses, pro-inﬂammatory cytokines and Gb3
levels in patients with Fabry disease under treatment with ERT.2. Material and methods
2.1. Subjects
The study was performed in 14 adult patients (11 male hemizy-
gotes and three female heterozygotes) with the classic form of FD
(median age 39.0 years; range 19–63) and 14 healthy controls
matched by age and sex (median age 28.5 years; range 22–58). All
patients were receiving ERT treatment (agalsidase alfa — Replagal®
0.2 mg/kg or agalsidase beta — Fabrazyme® 1.0 mg/kg) every two
weeks by intravenous infusion, for about 24.5 months (median;
range 2–77). At the moment of diagnosis, most of the patients pre-
sented the classic symptoms: angiokeratomas, hypohidrosis and
pain in extremities. Diagnosis of male patients was done by detection
of deﬁcientα-galactosidase A activity in plasma and conﬁrmed in leu-
cocytes. For the heterozygotes, diagnosis was conﬁrmed by molecular
analysis of GLA gene. Table 1 shows age, gender, mutation, estimated
glomerular ﬁltration rate by Modiﬁcation of Diet in Renal DiseaseTable 1
Gender, age, mutation, estimated glomerular ﬁltration rate and chronic kidney disease
stage from FD patients.
Gendera Age (years) Mutationb eGFR-MDRDc (mL/min/
1.73)
CKD staged
1 M 40 I133N 79 2
2 M 19 570del16 154 1
3 M 39 L36F 133 1
4 M 34 G328R 15 5
5 M 21 30delG 150 1
6 M 54 30delG 61 2
7 M 39 30delG 25 4
8 M 51 30delG 7 5
9 M 32 30delG 105 1
10 M 23 30delG 177 1
11 M 35 30delG 111 1
12 F 63 30delG 57 3
13 F 53 30delG 72 2
14 F 44 570del16 77 2
a M=male and F=female.
b GLA mutation.
c Glomerular ﬁltration rate (GFR) estimated by MDRD equation.
d Chronic kidney disease (CKD) stage according to the National Kidney Foundation.equation (eGFR-MDRD) and chronic kidney disease (CKD) stage
data from the patients.
Informed consent was obtained from the participants. The study
was approved by The Ethics Committee of the Hospital de Clinicas
de Porto Alegre (HCPA), RS, Brazil.
2.2. Samples collection and preparation
Occasional urine and heparinized blood samples were obtained
from patients immediately before the session of ERT. Samples were
obtained from controls concomitantly. Urine samples were collected
in sterile ﬂask and mixed before being deposited on 10–10 cm virgin
ﬁlter papers (Whatman 903), until saturation. The ﬁlter papers were
dried at room temperature (for at least 4–6 h) and stored at 4 °C until
Gb3 determination. The rest of urine collected was 1 mL aliquoted
and frozen at −80 °C until analysis.
Whole blood was centrifuged at 1000 ×g for 10 min and plasma
was removed by aspiration, aliquoted and frozen at−80 °C until bio-
chemical determinations. Erythrocytes were washed three times with
cold saline solution (0.153 mol/L sodium chloride) and lysates were
prepared by addition of 1 mL of distilled water to 100 μL of washed
erythrocytes and frozen at −80 °C until determination of GSH and
antioxidant enzymes' activities. For these determinations, superna-
tant (after centrifugation at 13,500 ×g for 10 min) was diluted in
order to contain approximately 0.5 mg/mL of protein.
2.3. Biochemical determinations
2.3.1. Malondialdehyde (MDA) plasmatic levels
MDA, an end product of lipoperoxidation, was measured by HPLC
following the method described by Esterbauer and Cheeseman [12]
with slight modiﬁcations. Six hundred microliters of 28% trichloroa-
cetic acid and 1.4 mL of distilled water were added to a 100 μL aliquot
of plasma. After centrifugation, supernatant was removed and MDA
was separated by HPLC using an amino-phase column with 30 mM
acetonitrile, Tris buffer pH 7.4 (1:9, v/v). The efﬂuent was monitored
at 267 nm, the wavelength of maximum absorption of the enolate
anion form of free MDA. The calibration was done with a standard so-
lution of MDA. Results were expressed as log of mM of MDA.
2.3.2. Urine di-tyrosine (di-Tyr) levels
In order to determine in urine the levels of protein oxidation, the
intensity of ﬂuorescence of di-Tyr was measured according to the
method described by Kirschbaum [13] using a SpectraMax M2e (Mo-
lecular Devices, USA) microplate reader at wavelengths of 315 and
410 nm (excitation and emission, respectively). Results were
expressed as log of ﬂuorescence units per mg urine creatinine (log
FU/mg Cr).
2.3.3. Carbonyl groups determination in plasma
The formation of carbonyl groups, a parameter of oxidative dam-
age to proteins, was measured based on the reaction of these groups
with dinitrophenylhidrazine (DNPH), as previously described by
Levine et al. [14]. The absorption of the product of reaction was mea-
sured in a spectrophotometer at 370 nm. Results were expressed as
nmol carbonyl/mg protein.
2.3.4. Total plasmatic level of sulfhydryl (SH) groups
The plasmatic concentration of SH groups was determined as de-
scribed by Aksenov and Markesbery [15]. The method is based on
the reduction of 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) by SH
groups into a yellow derivative (TNB) whose absorption is measured
spectrophotometrically at 412 nm. The SH content is inversely corre-
lated to oxidative damage to proteins. Results were reported as nmol
TNB/mg protein.
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Fig. 1. Antioxidant defenses [GSH (A), GPx (B) and SOD/CAT ratio (C)] in Fabry patients
under ERT (n=11) and controls (n=12–14). Data represent mean±SEM. *pb0.05,
**pb0.01 (Student's t test for unpaired samples) compared to the control group.
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In order to measure the levels of GSH, the main intracellular anti-
oxidant, lysates of erythrocytes were processed as described by
Browne and Armstrong [16] and the ﬂuorescence measured (λexcita-
tion=350 nm, λemission=420 nm) was compared to a calibration
curve prepared with GSH solutions. Results were expressed as
nmol/mg protein.
2.3.6. Erythrocyte glutathione peroxidase (GPx) activity
Erythrocyte GPx activity was measured by using a commercially
available kit (RANSEL®; Randox Lab). GPx catalyses the oxidation of
glutathione (GSH) to GSSG (oxidized glutathione). In the presence
of glutathione reductase (GR) and NADPH, the oxidized GSSG is con-
verted to the reduced formwith a concomitant oxidation of NADPH to
NADP. The decrease in absorbance after 1 and 2 min at 340 nm was
measured and results were expressed in U/mg protein.
2.3.7. Erythrocyte SOD/CAT ratio
Erythrocyte CAT activity was evaluated by observing the rate of
decrease in hydrogen peroxide (H2O2) absorbance in a spectropho-
tometer at 240 nm according to the method described by Aebi [17].
SOD activity was measured using the RANSOD® kit (Randox Lab, An-
trim, United Kingdom). The method is based on the formation of red
formazan from the reaction of 2-(4-iodophenyl)-3-(4-nitrophenol)-
5-phenyltetrazolium chloride and superoxide radical, which is pro-
duced by the incubation with the xanthine–xanthine oxidase reaction
system. The absorbance of the product is measured spectrophotomet-
rically at 505 nm. One unit of SOD corresponds to a 50% inhibition of
red formazan formation. The speciﬁc activity of SOD and CAT were
expressed as U/mg protein. Since both enzymes work in sequence
to reduce the superoxide anion to water, the ratio SOD/CAT was ap-
plied in order to verify the existence of an impairment that could
lead to a pro-oxidant status. Results were expressed as log of SOD/
CAT ratio.
2.3.8. Pro-inﬂammatory cytokines (IL-6 and TNF-α)
Plasma IL-6 and TNF-α levels were measured by the MILLIPLEX™
MAP Human Cytokine/Chemokine Kit (Millipore Corp., Billerica, Mas-
sachusetts, USA). Results were expressed in pg/mL.
2.3.9. Urinary Gb3 concentration
A 5-cm diameter ﬁlter paper disc was punched from each sample
and processed as described by C. Auray-Blais [18] with some modiﬁ-
cations. C17:0–Gb3 was used as internal standard (IS) and added to
the samples before injection into the LC-MS/MS (liquid chromatogra-
phy–tandem mass spectrometry) system. For LC, it was used an Alli-
ance 2695 system with stepwise gradient elution with mobile
phases A (ammonium acetate 2 mM+0.1% formic acid in water)
and B (ammonium acetate 2 mM+0.1% formic acid in methanol). A
Discovery® C8, 5 μm column (577508-U) was used for separation,
at 45 °C and the total analysis run time was 4.5 min. MS/MS was car-
ried out using a Quattro micro tandem quadrupole instrument (Wa-
ters Micromass, Manchester, UK) with electrospray ionization
operated in positive ion mode. The multiple reaction monitoring
mode was used for the measurement of IS and total Gb3 isoforms.
Gb3 levels were expressed as μg/mL and after divided by creatinine
(Cr) levels (mg/mL), ﬁnally resulting in μg Gb3/mg Cr. Results were
expressed as log of μg Gb3/mg Cr.
2.3.10. Urinary creatinine (Cr)
Cr was determined by picric acid method — Creatinine K kit of
Labtest® (Labtest Diagnóstica, Lagoa Santa, MG, Brazil). Urinary cre-
atinine reacts with picric acid under alkaline conditions producing
an orange color whose absorbance was determined in a spectropho-
tometer at 492 nm. Results were expressed as mg Cr/mL.2.3.11. Protein determination
Plasma and erythrocyte protein concentrations were determined,
respectively, by Biuret method — using the commercial kit of Labtest®
(Labtest Diagnóstica, Lagoa Santa, MG, Brazil) — and by the method of
Lowry [19].
2.4. Statistical analysis
All results were expressed as mean±standard error of the mean
(SEM). Normal distribution was tested by the Shapiro–Wilk test. Loga-
rithmic (log) transformation was done in data not normally distributed
in order to transform them in parametric. Unpaired Student's t test was
used for all comparisons between the two groups, using the ﬁrst sample
collected of each patient. Correlations betweenGb3 levels and the other
parameters were performed by Pearsons's correlation test.
Differences were considered signiﬁcant when pb0.05. Analyses
were performed by using the Statistical Package for the Social Sci-
ences (SPSS Inc., Chicago, IL, USA — SPSS version 19.0) software, and
graphics were constructed in GraphPad Prism (GraphPad Software
Inc., San Diego, CA, USA — version 5.0) software.
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3.1. Antioxidant defenses
The concentration of erythrocyte GSH, the main non-enzymatic
antioxidant in cells, was signiﬁcantly reduced in patients when com-
pared to the control group (Fig. 1A) [t(12.376)=3.240, pb0.01.
Erythrocyte GPx activity (Fig. 1B) was also reduced in patients [t
(23)=3.717, pb0.01] and directly correlated with GSH content
(r=0.290, pb0.05). Moreover, SOD/CAT ratio was increased in pa-
tients [t(12.191)=1.800, pb0.05], indicating a pro-oxidant status
(Fig. 1C) since the product of the reaction catalyzed by SOD, hydrogen
peroxide (H2O2), cannot be reduced to water in the same velocity by
CAT and then becomes available to oxidize biomolecules.3.2. Oxidative damage to biomolecules
To determine the oxidative damage to lipids and proteins wemea-
sured MDA and carbonyl groups in plasma and di-Tyr levels in urine.
Results showed that Fabry patients under treatment with ERT have
increased levels of oxidative damage to lipids (MDA plasma levels,
Fig. 2A) [t(11.403)=5.069, pb0.01] and proteins (di-Tyr in urine,
Fig. 2B; carbonyl groups plasma levels, Fig. 2C) [t(13.987)=2.160,
pb0.05; t(25)=3.986, pb0.01, respectively] when compared to con-
trols. No statistical difference was found in plasma sulfhydryl groups
(Fig. 2D) [t(22)=0.155, p>0.05] between patients and controls.3.3. Pro-inﬂammatory cytokines
Pro-inﬂammatory cytokines assayed in this study, TNF-α (Fig. 3A)
and IL-6 (Fig. 3B) were increased in Fabry patients when compared to
controls [t(21)=3.600, pb0.01; t(16)=3.000, pb0.01, respectively].Control Fabry
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Fig. 2. Oxidative damage to lipids [MDA (A)] and proteins [di-Tyr (B), carbonyl groups (C), s
Data represent mean±SEM. *pb0.05, **pb0.01 (Student's t test for unpaired samples) com3.4. Gb3 levels
To determine Gb3 levels we measured urinary Gb3 concentration.
Results showed that Fabry patients receiving ERT presented signiﬁcant
higher levels of urinary Gb3when compared to controls [t(19)=8.138,
pb0.01] (Fig. 4).
3.5. Correlations between oxidative stress, pro-inﬂammatory cytokines
and Gb3 levels
Gb3 levels were positively correlated with the plasma levels of IL-
6, MDA and carbonyl (Fig. 5A, B and C; r=0.971, pb0.01; r=0.622,
pb0.05; r=0.745, pb0.05, respectively). No signiﬁcant correlations
were found between Gb3 levels and the other parameters. IL-6 levels
were directly correlated with urinary levels of di-Tyr (Fig. 6A;
r=0.642, pb0.05) and inversely correlated with erythrocyte GPx ac-
tivity (Fig. 6B; r=−0.653, pb0.05).
4. Discussion
Lysosome storage disorders (LSDs) are well known monogenic
disorders caused by mutations that lead to an impairment of the ac-
tivity of lysosome enzymes and consequently, a progressive accumu-
lation of substrates. Although the primary cause of LSDs is
established, the mechanisms of how the intra-lysosomal accumula-
tion leads to cell and tissue dysfunction remain not completely clear
(including in Fabry disease) [8,10,20,21].
Vitner et al. published in 2010 a minireview focusing on the path-
ogenic cascades activated in LSDs [22]. These cascades include autop-
hagy, altered lipid trafﬁcking, endoplasmic reticulum (ER) stress,
autoimmune response, altered calcium homeostasis, inﬂammation
and oxidative stress. Lysosomes are quite vulnerable to oxidative
stress as a natural consequence of the physiological conditions under-
lying the organelle [8–10]. Probably, the accumulation of substratesControl Fabry
0.0
0.1
0.2
0.3
0.4
0.5 *
B
lo
g 
di
-T
yr
 (F
U/
mg
 C
r)
Control Fabry
0.0
1.0
2.0
3.0
4.0
D
Su
lfh
yd
ry
l (n
mo
l T
NB
/m
g p
ro
tei
n)
ulfhydryl groups (D)] in Fabry patients under ERT (n=12–14) and controls (n=6–13).
pared to the control group.
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Fig. 3. Pro-inﬂammatory cytokines [TNF-α (A) and IL-6 (B)] in Fabry patients under ERT (n=9–12) and controls (n=9–12). Data represent mean±SEM. **pb0.01 (Student's t test
for unpaired samples) compared to the control group.
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shown by Shen et al. [11]. The researchers found, by an in vitro
study in cultured cells, an increase of ROS and adhesion molecules
in response to Gb3.
Many studies have shown the involvement of oxidative stress in
the pathophysiology of more than a hundred of human diseases
[23], including cancer [24–27], inﬂammatory processes [23] and in-
born errors of metabolism (IEM) [28–33]. Recent studies of our
group showed evidences that oxidative stress may be involved in
the pathophysiology of mucopolysaccharidosis type II (MPS II) and
ERT seemed to protect against lipid and protein oxidative damage in
patients [32,33].
The aim of this study was to investigate oxidative stress parame-
ters, pro-inﬂammatory cytokines and Gb3 levels in Fabry patients
treated with ERT, in order to establish a possible relationship between
them.
We found decreased levels of antioxidant defenses (erythrocyte
GSH content and GPx activity) in FD patients when compared to con-
trols. The low GSH content implies low GPx activity and may lead to
higher susceptibility to oxidative damage. GSH is the most important
non-enzymatic antioxidant, being preferentially oxidized by reactive
species and then preserving more important biomolecules [34]. This
deﬁcient scavenger content of GSH, added to the increased SOD/CAT
ratio veriﬁed in this study indicates that probably hydrogen peroxide
(H2O2) is more available to oxidize biological molecules in Fabry pa-
tients. Furthermore, the low GPx activity conﬁrms this hypothesis of
H2O2 excess, since it is also the substrate of GPx. In the presence of
Fe2+, H2O2 yields the highly toxic hydroxyl radical (OH−), by the
called Fenton reaction. This radical attacks all types of biomolecules
around it, being extremely dangerous to the cell [34]. Hence, theControl Fabry
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Fig. 4. Gb3 urinary levels in Fabry patients under ERT and controls. Data represent
mean±SEM. **pb0.01 (Student's t test for unpaired samples) compared to the control
group.low GSH content and GPx activity and high SOD/CAT ratio presented
by Fabry patients probably contribute to the oxidative stress process.
In relation to oxidative damage to biomolecules, we found in-
creased levels of MDA and carbonyl in plasma of Fabry patients
when compared to controls. These data suggest that patients present
lipid peroxidation and protein damage in signiﬁcant higher levels.
The continued oxidation and fragmentation of fatty acid side chains
can produce aldehydes as MDA (formed from peroxidation of linole-
nic, arachidonic, or docosahexaenoic acids), that may lead to rupture
of lysosomal (and other organelles) membrane and bind avidly to
membrane proteins, inactivating enzymes and receptors and even at-
tack DNA, forming mutagenic lesions [34,35]. Thus, the increased
levels of MDA that we observed in Fabry patients must be a result
of the lysosome destabilization and also may be acting in the mainte-
nance of chain reactions with other molecules. Also, it is important to
emphasize that the positive correlation between Gb3 and MDA levels
that was found in this study suggest that Gb3 induces lipid peroxida-
tion in FD. Moreover, it was veriﬁed a signiﬁcant increase in MDA
levels in Fabry patients at diagnosis moment and under ERT when
compared to control group (data not shown). It allows us to suggest
that the observed effect is due to the disease and could explain, at
least in part, the pathophysiology of FD.
In this study, we veriﬁed a signiﬁcant increase in plasma carbonyl
groups as well as in urinary di-Tyr levels in Fabry patients. The alter-
ation of proteins by formation of carbonyl groups can be recognized
as “non-self” by the immune system and lead to autoimmune re-
sponse [23]. Some studies have shown that possibly the FD has an au-
toimmune component in its pathophysiology [36–39]. The positive
correlation found in this study between Gb3 and carbonyl levels sug-
gests that Gb3 may be acting also as an inductor of protein damage in
Fabry patients. We found no statistical difference between patients
and controls in what concern to sulfhydryl groups. Although the
amino acids containing this sulfur groups (cysteine and methionine)
are readily oxidized, literature suggest that this parameter may give
misleading data on the extent of oxidation in the case of chronic oxi-
dant stress [40]. In this case, the repair mechanism may compete ef-
fectively and differences are not evident, as occurred in this study.
On the other hand, the high carbonyl groups levels found in this
study are indicative of severe damage to proteins since heavily carbo-
nylated proteins tend to form high-molecular-weight aggregates that
are resistant to degradation by the proteasomal system [41]. More-
over, it is important to emphasize that it was veriﬁed no signiﬁcant
correlation between proteinuria — as well as other renal function pa-
rameters (urea, creatinine and eGFR-MDRD) — and the oxidative
stress parameters in these patients.
Flow cytometry studies revealed abnormalities in the number of
immune cell in Fabry patients [42]. Also, there are evidences that vas-
cular endothelium and leukocytes are under inﬂammatory activation
in FD [11,43]. Our ﬁndings concerning to the inﬂammatory cytokines
60
A
B
50
40
30
20
10
0
IL
-6
 (p
g/m
L)
60
50
40
30
20
10
0
IL
-6
 (p
g/m
L)
-,3 -,1 ,1 ,3
log Di-Tyr (FU/mg Cr)
,5 ,7
,03 ,05 ,08 ,10
GPx (U/mg prot)
,13
Fig. 6. Correlations between IL-6 and di-Tyr (A) and GPx activity (B) in Fabry patients
under ERT.
20
A
B
C
15
10
5
0
1,6 1,8 2,0
IL
-6
 (p
g/m
L)
2,0
1,8
1,6
1,4
,1600
,1400
,1200
,1000
1,0 1,2 1,4 1,6 1,8 2,0 2,2 2,4
1,5 1,8 2,0 2,3 2,5
lo
g 
M
DA
 (m
M)
Ca
rb
on
yl
 (n
mo
l/m
g p
ro
t)
2,2 2,4 2,6
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Fabry patients under ERT.
231G.B. Biancini et al. / Biochimica et Biophysica Acta 1822 (2012) 226–232IL-6 and TNF-α, both signiﬁcantly increased in Fabry patients, provide
evidence that the pro-inﬂammatory state occurs in these patients. Be-
sides, IL-6 was positively correlated with di-Tyr, which indicates oxi-
dative damage to proteins, as well as with Gb3 and negatively
correlated with GPx activity. These ﬁndings may suggest that the in-
ﬂammatory process is associated to protein damage and may be in-
duced by Gb3 in Fabry patients.
The present study conﬁrms the in vitro results fromShen et al. [11] in
what concern to Gb3 and oxidative stress induction and provides new
data to understand the pathophysiology of Fabry disease. Fabry patients
presented high lipid and protein oxidative damage, decreasedantioxidant defenses and increased inﬂammatory biomarkers. The
most signiﬁcant novelty in the present in vivo study is the presence of
correlations between the oxidative stress parameters, pro-
inﬂammatory cytokines and Gb3 levels. However, our results must be
interpreted carefully, since only treated patients were evaluated.
In conclusion, our results indicate that pro-oxidant and pro-
inﬂammatory states occur, are correlated and seem to be induced by
Gb3 in Fabry patients. Possibly, these data may provide new targets to
future therapeutic strategies in order to improve the quality of life of
Fabry patients. Further research and clinical trials are needed to reveal
how safe and effective would be the supplementation of antioxidants
in combination with ERT in Fabry patients.
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